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Background: Aortic stenosis (AS) is a common valvular abnormality and TAVI is being increasingly used to treat patients considered too high risk for conventional surgery.   We aimed to assess the prevalence of comorbid conditions in patients undergoing Transcatheter aortic valve implantation (TAVI) using Charlson Comorbidity Index (CCI) and to assess their impact on clinical and procedural outcomes.  
Methods: We analyzed 158 patients who underwent a TAVI at our institution between June 2009 and September 2015 to define their co-morbid burden as measured with CCI, and study its impact on procedural characteristics and mortality at 30-days.  
Results: 158 patients with a mean age of 82±8 years and a mean CCI score of 2.67 underwent a TAVI. Only 12/158 patients had a CCI of 0. The commonest cardiovascular comorbidities were previous myocardial infarction (24%), congestive heart failure (15%) and diabetes mellitus (23%) whilst the commonest non-cardiovascular comorbidities were renal disease (46%) and COPD (29%).   After multivariable adjustment, CCI was not independently associated with adverse clinical outcomes.  The addition of CCI to scoring systems such as Logistic EuroScore (LES) and Society of Thoracic Surgeons (STS) risk models improved the area under the curve from 0.75 (95%CI:0.44-1.00) and 0.83 (95%CI: 0.64-1.00) to 0.78 (95%CI:0.53-1.00) and 0.89 (95%CI:0.78-1.00) respectively.
Conclusions: The burden of comorbid conditions in patients undergoing TAVI is significant.  CCI score was not independently associated with a higher risk of death but can be useful in addition to LES and STS risk models in informing decision making on selection of patients for TAVI. 





Aortic stenosis is the commonest form of valvular heart disease in Europe and in North America, affecting between 2-7% of the population over the age of 65 [1,2]. In patients with symptomatic severe aortic stenosis, surgical aortic valve replacement (SAVR) remains the definitive treatment with a mortality of only 1-3% in younger patients and a mortality of 4-8% in selected patients over the age of 70 [3-5]. In patients with a high surgical risk, transcatheter aortic valve implantation (TAVI) via the transfemoral or transapical route achieves similar survival at 1 year to SAVR [6].  In patients deemed inoperable due to a prohibitive risk, TAVI significantly reduces mortality and symptoms compared to best medical therapy [7].  Both American and European guidelines recommend TAVI in patients with prohibitive or high surgical risk for SAVR after appropriate review by a heart team [1,8]. 
TAVI procedures have a mortality rate of between 6-15% [7,9,10] and complications including stroke, requirement for permanent pacemaker, vascular access complications and paravalvular regurgitation [6,7].
The prevalence of aortic stenosis increases with age [11]. Comorbidity burden also significantly increases with age.  In a Medicare population of over 1 million, 85% of patients over the age of 65 had at least 1 significant comorbid condition and 65% of patients had 2 or more significant comorbid conditions [12]. Therefore, it is unsurprising that many patients with aortic stenosis are elderly with multiple co-morbidities [13]. The presence of significant comorbidities can make the selection of appropriate patients who would benefit from TAVI challenging and may influence outcomes. Previous studies in patients undergoing TAVI have considered only co-morbidities as either cardiovascular risk factors and or the presence of coronary artery disease that frequently coexists with aortic stenosis rather than systematic measures of general co-morbidity burden [14,15]. The Charlson co-morbidity index (CCI) is a measure of co-morbidity burden, which quantifies  the prognostic impact of 22 comorbid conditions on the basis of their number and their individual prognostic impact by means of a score that was developed as a prognostic indicator for patients with a variety of medical conditions [16]. A score of zero indicates that no comorbidities were present whilst a score of 33 is the maximum; a higher score is associated with a higher risk of death. The CCI is well validated and has been shown to be a good predictor of outcome in a range of conditions including surgery for small cell lung cancer [17], surgery following hip fracture [18], percutaneous coronary intervention (PCI)[19] and patients with aortic stenosis [20].  It has also been shown that CCI has a similar ability to assess risk of in-hospital mortality to EuroSCORE in patients undergoing CABG [21].
However, less is known about the distribution of other comorbid conditions in patients undergoing TAVI and their association with clinical outcomes with limited data derived from small single centre registries. CCI has only been evaluated in 3 studies of patients undergoing TAVI.  A high CCI has been shown to be associated with a worse outcome in 2 small single centre studies [22,23], although another study failed to observe such a relationship [24].  We sought to assess the prevalence and distribution of comorbid conditions in patients undergoing TAVI using CCI and to assess their impact on clinical and procedural outcomes.
Methods
This study analyzed all patients who underwent transcatheter aortic valve implantation (TAVI) at the Royal Stoke Hospital, University Hospitals of North Midlands (UHNM) between June 2009 and September 2015. The procedures were performed under general anesthetic using the Sapien and Sapien XT valves (Edwards Lifesciences, Irvine, California, USA) via the transfemoral route in 89% and the transapical route in 11% of cases.  Data was collected from our local TAVI registry that is submitted annually to the National Institute of Cardiovascular Outcomes Research for the UK TAVI Registry for national reporting25. Using their NHS number as the Link, electronic patient records for these patients were retrieved from the hospital PAS system and linked to their NICOR TAVI dataset records.  The components of CCI include: previous myocardial infarction, congestive cardiac failure, peripheral vascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes, renal disease, hemiplegia, leukemia, lymphoma, solid tumor with or without metastatic disease, liver disease and Acquired Immune Deficiency Syndrome (AIDS) status (Table 1).  
Outcomes collected include Valve Academic Research Consortium (VARC)-2 combined safety endpoints (mortality, all cause stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complication, valve-related dysfunction) [26], 30-day mortality, intra-operative radiation dose, intra-operative radio-contrast exposure, length of procedure and length of stay.
Statistical analysis
Statistical analysis was performed on STATA 13.1 (College Station, Texas) and R version 3.3.1 [27].  The CCI score was calculated for each patient and the frequency of each CCI score in the cohort is shown graphically.  The patients were then split into four groups based on CCI score of: CCI=0, CCI=1, CCI=2 and CCI≥3, which are based on commonly used categories in existing studies [28-30]. Descriptive statistics were presented for each variable per CCI group.  Differences across CCI groups were tested using Fisher's Exact Test and one-way analysis of variance for categorical and continuous variables, respectively. 
Univariate and multivariable regression analyses were performed to determine the association between incremental unit increases in CCI score and each outcome. Binary outcomes (30-day mortality and VARC-2 composite early safety) were analyzed using logistic regression, continuous variables (intra-operative radiation dose and intra-operative radio-contrast exposure) were analyzed using linear regression and time-to-event outcomes (length of stay and length of procedure) were analyzed using Cox proportional hazards models. In the latter case, the proportionality assumption was checked.  Multivariable models adjusted for age, sex, apical access and any of following demographic or procedural variables that were identified significant (p<0.05) by univariable analysis for each outcome: smoking status, calcification of ascending aorta, atrial fibrillation/ flutter, previous BAV, NYHA Class ≥III, BMI, CCS Class 4, aortic valve area, LVEF<50%, one or more diseased vessels, left main stem disease and non-elective procedure indication. Additionally, a sensitivity analysis was performed that analyzed all outcomes in Transfemoral access patients only. Rates of the individual components of VARC-2 were also evaluated according to CCI group.
The predicted risk of mortality was retrospectively calculated for each patient using the Logistic EuroScore (LES) and Society of Thoracic Surgeons (STS) risk models using the variables and coefficients previously reported [31,32]. Any LES or STS variable that was not available in the dataset or missing for a patient was assumed risk factor absent. Subsequently, CCI total was added into to each risk model by fitting a logistic regression model to 30-day mortality with both the linear predictor of that risk model and CCI total as covariates [33]. The area under the receiver operator characteristic curve (AUC) was calculated for the LES and STS, which were compared with those for the updated risk models (i.e. those with CCI added) using a DeLong comparison [34]. This was similarly undertaken for the VARC-2 composite endpoint.
Results
Between 2009 and 2015, 158 patients with a mean age of 82.1 (SD 7.5) years underwent TAVI at our centre. The majority of patients were male (64%) and their CCI scores ranged from 0 (no comorbidity) to 8 (very significant comorbidity) (Figure 1).  The mean CCI was 2.67 (SD 1.72). 
Table 2 shows the characteristics of the cohort under examination as a whole cohort and across the four defined CCI groups.  There were 12 (8%) patients with a CCI of 0, 35 patients (22%) with a CCI of 1, 29 patients (18%) with a CCI of 2, 36 patients (23%) with a CCI of 3 and 46 (29%) patients with CCI of 4 or above.  There was no significant difference in age or sex of patients between the CCI groups (p=0.194, p=0.117).  The majority were also either current or ex-smokers (55%) and overweight with a mean body mass index (BMI) of 27.6.  Smoking status (p<0.001), creatinine (p<0.001), previous BAV (p=0.015) and previous PCI (p=0.027) were all significantly different between CCI groups.  Conversely, BMI (p=0.272), cardiac operation (p=0.593), aortic valve area (p=0.975), atrial fibrillation/flutter(p=0.387) and extra-cardiac arteriopathy (p=0.199) were not significantly different between the groups, and neither were procedural variables of emergency procedure (p=0.754) and apical procedure (p=0.556).  The Logistic EuroSCORE and STS score were also similar across the groups (p=0.099, p=0.067). 
 Table 3 shows the prevalence of the elements making up the CCI in our cohort. The commonest cardiovascular comorbidities were previous myocardial infarction (38 patients, 24%), congestive heart failure (24 patients, 15%) and diabetes mellitus (37 patients, 23%); the commonest non-cardiovascular comorbidities were chronic renal disease (73 patients, 46%) and COPD (46 patients, 29%) (Table 3). Peripheral vascular disease (p<0.001), COPD (p=0.004), diabetes (p<0.001), renal disease (p<0001) and solid tumor (p<0.001) were significantly more common amongst the CCI≥3 group; there were no significant differences in the prevalence of the other risk factors.
When unadjusted patient outcomes were considered according to comorbid burden, no significant differences were seen between the CCI groups in VARC-2 (p=0.903), 30-day mortality (p=0.583),  contrast (p=0.731), mean procedure length (p=0.051) or mean length of stay (p=0.375) (Table 3).  A significant difference was observed for radiation dose (p=0.021). Additionally, there was no significant difference in the cumulative event rates of length of stay (log-rank test, p=0.894) or in length of procedure (log-rank test, p=0.261) by CCI group. Rates of the individual components of VARC-2 were also evaluated according to CCI group are shown in Supplementary Table 1.
Increases per unit CCI score were significantly associated with increased 30-day mortality (p=0.009), radiation dose (p=0.006) and length of procedure (p=0.002) when adjusted for age and sex (Table 4). However, after multivariable adjustment for age, sex, apical access and other significant predictors, unit increases in CCI were not significantly associated with outcome. The multivariable adjustment for VARC-2 composite early safety, 30-day mortality and contrast all included age, sex and apical access. Multivariable adjustment of radiation dose included age, sex apical access and smoking status. Length of stay was adjusted for age, sex, apical access, smoking status, aortic valve area and left main stem disease. Finally, length of procedure was adjusted for age, sex, apical access, smoking status and non-elective procedure indication. The sensitivity analyses that examined only transfemoral access patients indicated no significant differences in outcomes for unit increases in CCI, after multivariable adjustment. 
The AUC for 30-day mortality prediction were 0.75 (95% CI: 0.44, 1.00) and 0.83 (95% CI: 0.64, 1.00) for LES and STS, respectively. The addition of CCI total into the LES and STS score increased the AUCs to 0.78 (95% CI: 0.53, 1.00; DeLong p-value=0.71), and 0.89 (95% CI: 0.78, 0.99; DeLong p-value=0.43), respectively.  Similarly, for VARC-2 composite early safety, the AUC for LES was 0.57 (95% CI: 0.41, 0.74) and for STS score was 0.46 (95% CI: 0.30, 0.63). Again, adding CCI increased these to 0.60 (95% CI: 0.46, 0.75; DeLong p-value=0.59) and 0.58 (95% CI: 0.43, 0.73; DeLong p-value=0.36) for LES and STS, respectively.
Discussion
Our analysis showed that patients undergoing TAVI had a large range in the severity of comorbidities as measured by the CCI.  A CCI score of >2 is considered to represent significant comorbidity and our patients had a mean CCI of 2.67 (SD 1.72).  Unsurprisingly, less than 8% of patients undergoing TAVI at our centre had no comorbidities, since patients with very low comorbid burden are likely to have been appropriate for SAVR and patients with very high scores would have a very poor prognosis regardless of aortic valve intervention. Patients with higher CCI were significantly more likely to have smoked, have worse renal function, worse left ventricular function and to have had a previous BAV.  This population of multi-morbid elderly patients (mean age 82) is likely to be representative of the types of patients undergoing the procedure elsewhere. Our 30-day mortality rate of less than 5%, and VARC-2 safety endpoints observed in 11% of patients is broadly similar to patient groups and outcomes reported elsewhere [6,7,35-37].  Although there was no difference in any unadjusted outcome measure between the 4 groups, we observed a significant association between higher CCI (per unit increase) and higher radiation dose, length of procedure and 30-day mortality in both unadjusted analyses, and those adjusted for age and gender.  However, after multivariable analysis (age, sex, apical access and other significant variables), CCI score was not significantly linked to any outcome measure, although non-significant trends were evident.  
Our analysis found that CCI score contributes to predicting mortality following TAVI when added to established risk scoring systems such as LES and STS.  The LES uses a composite score based on a combination of patient demographics (age and sex), cardiac (previous cardiac surgery, endocarditis, recent MI, LV function, presence of unstable angina) and extra-cardiac comorbidities (COPD, PVD, neurological dysfunction, renal failure, pulmonary hypertension) and details of planned surgical procedure (emergency, valve surgery, aortic surgery, post-infarct septal defect) to give a risk of 30-day (or in-hospital) mortality following cardiothoracic surgery [31].  The STS score also gives a risk of 30 day mortality but uses a more extensive list of 40 patient and operative variables [32].  Both scoring systems are good at predicting operative mortality following open surgery[38] but have are suboptimal if used in assessment of patients for TAVI [39].  In this study, the AUC for 30-day mortality is 0.75 (95% CI: 0.44, 1.00) and 0.83 (95% CI: 0.64, 1.00) for LES and STS, which improve to 0.78 (95% CI: 0.53, 1.00) and 0.89 (95% CI: 0.78, 1.00) respectively with the addition of CCI.  Similarly, for VARC-2 composite early safety, the AUC for LES was 0.57 (95% CI: 0.41, 0.74) and for STS score was 0.46 (95% CI: 0.30, 0.63). Adding CCI increased these to 0.60 (95% CI: 0.46, 0.75) and 0.58 (95% CI: 0.43, 0.78). 
Research by Bouleti et al examining survival following TAVI has shown that a higher CCI is associated with higher rates of late (non-hospital) mortality following TAVI [22].  Their study of 123 patients with a mean age of 81.5±8.4 underwent TAVI using a combination of the Sapien valve (Edwards Lifesciences) and the CoreValve (Medtronic, Minneapolis, USA) via the transfemoral (68.3%), transapical (30.1%), subclavian and retroperitoneal routes (1.6%).Their patients were significantly more comorbid than our own with a mean CCI of 5.3±2.3 and therefore had a relatively high in-hospital mortality of 13%.  During late follow-up, they found that CCI was associated with a higher rate of mortality for as long as 6 years (CCI per 1 unit increase had a hazard ratio of 1.12, p=0.03) and that the majority of deaths in this population of patients were attributable to non-cardiac causes.  Their outcome data did not include radiation dose or length of procedure.  
Munoz et al also found that high CCI is associated with increased mortality after 30 days [23].  Their study of 133 high risk patients with a mean age of 79.5±6.7 years underwent TAVI with the CoreValve (Medtronic, Minneapolis, USA). As well as using a different valve, their procedure differed from ours in that the majority of their patients (96%) underwent the procedure under local anesthetic with sedation rather than general anesthetic. Most (91%) of the patients had TAVI via the femoral route with subclavian access used in the remainder.  Their patients also had significant comorbidities with a mean CCI of 3.57±1.9 which is higher than our own cohort.  Mortality at 30 days was 4.5% with CCI having a significant effect (OR 1.44, p<0.10).
The two studies described  found a clear association between CCI and mortality following TAVI.  Our study did not find any clear association between CCI and mortality following multivariate analysis.  This may have been related to the lower risk population that our TAVI cohort represented compared to the two studies described.  Another recent study by Hiltrop et al examined 145 patients with a median age of 84 (IQR 80-87) undergoing TAVI [24] in which cases were performed under general anesthetic using the Sapien or Sapien XT valves (Edwards Lifesciences).  Patients had a similar CCI (median 3, IQR 2-4) with 61% of access via the femoral artery and 39% transapical and the authors reported no difference in the baseline CCI between those patients who died and those who survived up to 2 years in following TAVI.
Our study adds significant information to the field of outcome following TAVI in elderly, heavily comorbid patients.  Although we did not find a statistically significant association between CCI and outcome following TAVI, there was a trend towards higher radiation dose, length of procedure and 30-day mortality.  We also found that the addition of CCI to either the LES or the STS improved the model in predicting death within 30 days following TAVI.  This is unsurprising as increasing age is associated both with severe aortic stenosis and other comorbidities.  The leading causes of death within 30-days of a TAVI procedure are infection, heart failure, stroke and multi-organ failure [40,41].  Heavily comorbid patients can reasonably be expected to be more at risk from these conditions as kidney disease, cerebrovascular disease and heart failure make up part of the scoring of CCI.    Our study has limitations.  It reflects the experience of a single centre using the Sapien and Sapien XT TAVI devices and will be subject to biases around local practices, particularly the type of patients accepted onto the TAVI program by our heart team.  Additionally, we had only a modest sample size, reflecting the lower number of these procedures compared to other interventions. It is also possible that there are factors which influence outcomes in TAVI such as frailty which we were unable to capture. It has been shown that frailty (measured by grip strength, gait speed, serum albumin and activities of daily living) can be associated with long term outcome after TAVI [42].  In addition, we were also unable to capture any post-procedure management which could have affected 30-day mortality and safety endpoints.  We found that higher CCI score was associated with significantly higher radiation dose and reduced length of procedure but after adjustments these were no longer significant. There are other important factors such as operator experience which may influence length of procedure and radiation dose which we were unable to account for in the current study.
Conclusions
Our work suggests that patient undergoing TAVI have significant comorbid burden that is mainly cardiovascular.  The most common non-cardiovascular comorbidities are renal impairment and COPD.    A high CCI is associated with a non-statistically significant trend towards a longer procedure, higher radiation dose and higher 30-day mortality.  The addition of CCI to other scoring systems such as LES or STS improved the performance of the models.  It is important that comorbidity burden is carefully evaluated in an objective manner as part of the assessment of patients prior to TAVI.
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Chronic obstructive pulmonary disease	1
Connective tissue disease	1
Peptic ulcer disease	1
Diabetes mellitus	1 if uncomplicated
2 if end-organ damage






Liver disease	1 if mild





Table 2: Participant characteristics by Charlson Comorbidity Index
Variable	CCI=0-1 (N=47)	CCI=2-3 (N=65)	CCI≥4 (N=46)	Whole Cohort (N=158)	p-value
Age (SD)	83.8 (6.84)	81.5 (8.44)	81.3 (6.68)	82.1 (7.53)	0.194
Male (%)	27 (57%)	39 (60%)	35 (76%)	101 (64%)	0.117
Smoker (%)Ex-smokerCurrent smoker	19 (41%)0 (0%)	25 (38%)6 (9%)	35 (76%)2 (4%)	79 (50%)
8 (5%)	<0.001
BMI (SD)	26.7 (4.57)	28.2 (5.82)	27.8 (4.91)	27.6 (5.24)	0.272
NYHA ≥III (%)	46 (98%)	62 (95%)	43 (93%)	151 (96%)	0.491
Mean Creatinine (SD)	76.4 (14.4)	127.6 (100.8)	152.9 (90.7)	119.8 (86.4)	<0.001
Aortic Valve Area (SD)	0.75 (0.25)	0.76 (0.25)	0.76 (0.21)	0.76 (0.24)	0.975
Atrial fibrillation/flutter (%)	14 (30%)	25 (38%)	20 (43%)	59 (37%)	0.387
Extracardiac arteriopathy (%)	13 (28%)	14 (22%)	17 (37%)	44 (28%)	0.199
LVEF < 50% (%)	19 (40%)	27 (42%)	27 (59%)	73 (46%)	0.127
Previous BAV (%)	9 (19%)	14 (22%)	20 (43%)	43 (27%)	0.015
Previous PCI (%)	6 (13%)	17 (26%)	17 (37%)	40 (25%)	0.027
Previous cardiac operation (%)	17 (36%)	18 (28%)	13 (28%)	48 (30%)	0.593
Emergency (%)	0 (0%)	1 (2%)	1 (2%)	2 (1%)	0.754
Apical procedure (%)	4 (9%)	6 (9%)	7 (15%)	17 (11%)	0.556
Logistic EuroSCORE (SD)	17.0 (9.0)	18.9 (13.9)	22.8 (16.2)	19.5 (13.5)	0.099






Table 3: Charlson Comorbidity Index variables and outcomes for participants

Variable in Charlson Comorbidity Index	CCI=0-1 (N=47)	CCI=2-3 (N=65)	CCI≥4 (N=46)	Whole Cohort (N=158)	p-value
Previous MI (%)	9 (19%)	13 (20%)	16 (35%)	38 (24%)	0.142
Congestive Cardiac Failure (%)	4 (9%)	9 (14%)	11 (24%)	24 (15%)	0.121
PVD (%)	2 (4.3%)	6 (9.2%)	15 (32.6%)	23 (14.6%)	<0.001
Cerebrovascular disease (%)	6 (13%)	16 (26%)	20 (43%)	43 (27%)	0.004
Dementia (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-
COPD (%)	7 (15%)	18 (28%)	21 (46%)	46 (29%)	0.004
Connective Tissue Disease (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-
Peptic Ulcer Disease (%)	1 (2%)	2 (3%)	4 (9%)	7 (4%)	0.298
Diabetes without end organ damage (%)Diabetes with end organ damage (%)	6 (13%)0 (0%)	10 (15%)0 (0%)	4 (9%)17 (37%)	20 (13%)17 (11%)	<0.001
Renal Disease (%)	0 (%)	35 (54%)	38 (83%)	73 (46%)	<0.001
Hemiplegia (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-
Leukaemia (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-
Lymphoma (%)	0 (0%)	2 (3%)	1 (2%)	3 (2%)	0.631
Solid Tumour (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<0.001
Solid Tumour + metastasis (%)	0 (0%)	5 (8%)	12 (26%)	17 (11%)	
Liver Disease Mild (%)	0 (0%)	0 (0%)	1 (2%)	1 (1%)	0.083
Liver Disease Moderate -Severe (%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	
AIDS (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-
Outcomes
VARC-2 (%)	5 (11%)	7 (11%)	6 (13%)	18 (11%)	0.903
30-day mortality (%)	1 (2%)	2 (3%)	3 (7%)	6 (4%)	0.583
Radiation dose (SD)	3526 (2636)	3937 (5195)	5195 (3552)	4183 (3046)	0.021
Contrast (SD)	44.4 (28.8)	45.9 (35.1)	41.3 (22.1)	44.1 (29.7)	0.731
Length of Procedure (SD)	87.0 (29.8)	87.7 (34.3%)	103.6 (47.1)	92.1 (37.8)	0.051





Table 4: Linear and logistic regression for outcomes by Charlson Comorbidity Index
Outcome from logistic regression	N	Odds ratio (95% CI)	p-value
30-day mortality     Unadjusted     Age Adjusted     Age & Sex Adjusted     Multivariable Adjusted*	158158158158	1.69 (1.08, 2.76)1.72 (1.10, 2.81)1.91 (1.20, 3.24)1.62 (0.99, 2.74)	0.0230.0200.0090.055
VARC-2 composite early safety     Univariate     Age Adjusted     Age & Sex Adjusted     Multivariable Adjusted*	158158158158	1.22 (0.93, 1.61)1.24 (0.94, 1.64)1.25 (0.94, 1.67)1.17 (0.87, 1.57)	0.1510.1260.1140.284
Outcomes from linear regression	N	Coefficient (95% CI)	p-value
Radiation dose      Univariate     Age Adjusted     Age & Sex Adjusted     Multivariable Adjusted*	157157157157	431 (159, 704)443 (169, 718)377 (109, 644)224 (-54, 501)	0.0020.0020.0060.114
Contrast      Univariate     Age Adjusted     Age & Sex Adjusted     Multivariable Adjusted*	156156156156	-0.04 (-2.79, 2.71)0.45 (-2.25, 3.15)0.39 (-2.35, 3.13)0.60 (-2.17, 3.37)	0.9790.7430.7810.670
Outcomes from Cox proportional hazards model	N	Hazard Ratio (95% CI)	p-value
Length of Procedure     Univariate     Age Adjusted     Age & Sex Adjusted     Multivariable Adjusted*	156156156156	0.88 (0.80, 0.96)0.86 (0.78, 0.94)0.86 (0.78, 0.94)0.90 (0.81, 1.00)	0.0050.0010.0020.051
Length of Stay     Univariate     Age Adjusted     Age & Sex Adjusted     Multivariable Adjusted*	158158158158	0.96 (0.88, 1.05)0.92 (0.84, 1.01)0.94 (0.85, 1.03)0.99 (0.90, 1.10)	0.3300.0850.1620.869
* Multivariable Adjusted: such models included age, sex, transapical access indication and any other demographic or procedural variables identified significant (p<0.05) by univariable analysis for each outcome. Bold items indicate significant results.


Supplementary Table 1: Components on VARC-2 by Charlson Comorbidity Index
Variable	CCI=0-1 (N=47)	CCI=2-3 (N=65)	CCI≥4 (N=46)	Whole Cohort (N=158)	p-value
Mortality	1 (2%)	2 (3%)	3 (7%)	6 (4%)	0.583
All cause stroke	1 (2%)	2 (3%)	1 (2%)	4 (3%)	1.000
Life-threatening bleeding	0 (0%)	1 (2%)	2 (4%)	3 (2%)	0.373
Acute kidney injury	1 (2%)	0 (0%)	2 (4%)	3 (2%)	0.192
Coronary artery obstruction	1 (2%)	0 (0%)	0 (0%)	1 (1%)	0.589
Major vascular complication	1 (2%)	1 (2%)	2 (4%)	4 (3%)	0.691
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